Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11063925rdf:typepubmed:Citationlld:pubmed
pubmed-article:11063925lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:11063925lifeskim:mentionsumls-concept:C0006104lld:lifeskim
pubmed-article:11063925lifeskim:mentionsumls-concept:C0205145lld:lifeskim
pubmed-article:11063925lifeskim:mentionsumls-concept:C0034783lld:lifeskim
pubmed-article:11063925lifeskim:mentionsumls-concept:C0009014lld:lifeskim
pubmed-article:11063925lifeskim:mentionsumls-concept:C1167622lld:lifeskim
pubmed-article:11063925lifeskim:mentionsumls-concept:C2003941lld:lifeskim
pubmed-article:11063925lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:11063925pubmed:issue6lld:pubmed
pubmed-article:11063925pubmed:dateCreated2000-12-8lld:pubmed
pubmed-article:11063925pubmed:abstractTextClonidine is a partial agonist at brain alpha(2)-adrenoceptors (alpha(2)AR), but also has high affinity (K(D) = 51 nM) in homogenate binding assays for non-adrenergic imidazoline-binding sites (I-sites; imidazoline receptors). Herein, an autoradiographic comparison of [3H]-clonidine binding to I-sites and alpha(2)AR in sections of human brain is reported. For I-sites, the adrenergic component of 50 nM [3H]-clonidine binding was masked with either 60 microM norepinephrine (NE; alpha(2)AR agonist) or 12.5 microM methoxy-idazoxan (MIDX; selective alpha(2)AR antagonist), whereas the remaining non-adrenergic sites were studied by displacement with 20 microM cirazoline. Levels of [3H]-clonidine binding to alpha(2)AR and I-sites, determined in adjacent tissue sections, were positively correlated across 27 brain regions (p = 0.0003; r(2) = 0.385). The principal olivary nucleus and the rostral portion of the ventrolateral medulla had highest ratios of I-sites: alpha(2)AR (>4:1). Quantitative transepts drawn across hippocampal images revealed alpha(2)AR enrichments in the CA-1 and inner molecular layers of the dentate gyrus-areas not enriched in I-sites. Competition curves were generated for I-sites in caudate sections using 10 ligands known to distinguish between I(1) and I(2) subtypes. The rank-order of affinities were cirazoline > harmane > BDF6143 > idazoxan = tizanidine (affinities of agmatine, efaroxan, moxonidine, NE, and oxymetazoline were too low to be reliable). Only the endogenous I-site ligand, harmane, had a monophasic displacement curve at the non-adrenergic sites (Ki = 521 +/- 12 nM). In conclusion: 1) the distribution of non-adrenergic [3H]-clonidine binding sites in human brain sections was correlated with, but distinct from alpha(2)AR; and 2) the affinities of these sites was distinct from alpha(1)AR, alpha(2)AR, I(1) or I(2) sites as previously defined in membrane binding assays. The properties of this non-adrenergic [3H]-clonidine binding site are consistent with I-sites previously labeled by [3H]-cirazoline in rat brain.lld:pubmed
pubmed-article:11063925pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11063925pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11063925pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11063925pubmed:languageenglld:pubmed
pubmed-article:11063925pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11063925pubmed:citationSubsetIMlld:pubmed
pubmed-article:11063925pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11063925pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11063925pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11063925pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11063925pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11063925pubmed:statusMEDLINElld:pubmed
pubmed-article:11063925pubmed:monthDeclld:pubmed
pubmed-article:11063925pubmed:issn0893-133Xlld:pubmed
pubmed-article:11063925pubmed:authorpubmed-author:OrdwayG AGAlld:pubmed
pubmed-article:11063925pubmed:authorpubmed-author:HalarisAAlld:pubmed
pubmed-article:11063925pubmed:authorpubmed-author:PiletzJ EJElld:pubmed
pubmed-article:11063925pubmed:authorpubmed-author:ZhuHHlld:pubmed
pubmed-article:11063925pubmed:authorpubmed-author:DuncanB JBJlld:pubmed
pubmed-article:11063925pubmed:issnTypePrintlld:pubmed
pubmed-article:11063925pubmed:volume23lld:pubmed
pubmed-article:11063925pubmed:ownerNLMlld:pubmed
pubmed-article:11063925pubmed:authorsCompleteYlld:pubmed
pubmed-article:11063925pubmed:pagination697-708lld:pubmed
pubmed-article:11063925pubmed:dateRevised2011-5-18lld:pubmed
pubmed-article:11063925pubmed:meshHeadingpubmed-meshheading:11063925...lld:pubmed
pubmed-article:11063925pubmed:meshHeadingpubmed-meshheading:11063925...lld:pubmed
pubmed-article:11063925pubmed:meshHeadingpubmed-meshheading:11063925...lld:pubmed
pubmed-article:11063925pubmed:meshHeadingpubmed-meshheading:11063925...lld:pubmed
pubmed-article:11063925pubmed:meshHeadingpubmed-meshheading:11063925...lld:pubmed
pubmed-article:11063925pubmed:meshHeadingpubmed-meshheading:11063925...lld:pubmed
pubmed-article:11063925pubmed:meshHeadingpubmed-meshheading:11063925...lld:pubmed
pubmed-article:11063925pubmed:meshHeadingpubmed-meshheading:11063925...lld:pubmed
pubmed-article:11063925pubmed:meshHeadingpubmed-meshheading:11063925...lld:pubmed
pubmed-article:11063925pubmed:meshHeadingpubmed-meshheading:11063925...lld:pubmed
pubmed-article:11063925pubmed:meshHeadingpubmed-meshheading:11063925...lld:pubmed
pubmed-article:11063925pubmed:meshHeadingpubmed-meshheading:11063925...lld:pubmed
pubmed-article:11063925pubmed:meshHeadingpubmed-meshheading:11063925...lld:pubmed
pubmed-article:11063925pubmed:meshHeadingpubmed-meshheading:11063925...lld:pubmed
pubmed-article:11063925pubmed:meshHeadingpubmed-meshheading:11063925...lld:pubmed
pubmed-article:11063925pubmed:meshHeadingpubmed-meshheading:11063925...lld:pubmed
pubmed-article:11063925pubmed:year2000lld:pubmed
pubmed-article:11063925pubmed:articleTitleAutoradiographic comparison of [3H]-clonidine binding to non-adrenergic sites and alpha(2)-adrenergic receptors in human brain.lld:pubmed
pubmed-article:11063925pubmed:affiliationDepartments of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS 39216-4505, USA.lld:pubmed
pubmed-article:11063925pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11063925pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:11063925pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed